Kidney Week Educational Symposia-Anti-CD38 Therapies for IgAN: Is Durable Remission Possible?

Video Transcription

Video Summary

<strong style="box-sizing: border-box; font-weight: bold; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;">Moderator(s):</strong><span style="color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff; float: none; display: inline;"> Shuta Ishibe</span><br style="box-sizing: border-box; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;" /><br style="box-sizing: border-box; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;" /><strong style="box-sizing: border-box; font-weight: bold; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;">Presentation(s):</strong><br style="box-sizing: border-box; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;" />
<ul style="box-sizing: border-box; margin-top: 0px; margin-bottom: 10px; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;">
<li style="box-sizing: border-box;"><strong style="box-sizing: border-box; font-weight: bold;">Introduction</strong> - Shuta Ishibe</li>
<li style="box-sizing: border-box;"><strong style="box-sizing: border-box; font-weight: bold;">CD38 and Plasma Cells in IgAN: Pathogenesis to Therapeutic Target</strong> - Heather Reich</li>
<li style="box-sizing: border-box;"><strong style="box-sizing: border-box; font-weight: bold;">Clinical Rationale, Emerging Data, and Clinical Context for CD38-Directed Therapy in the Evolving Landscape of IgAN Therapies</strong> - J&uuml;rgen Floege</li>
</ul>
<em style="box-sizing: border-box; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;">Support is provided by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.</em>&nbsp;

Asset Subtitle

Moderator(s): Shuta Ishibe

Presentation(s):

Introduction - Shuta Ishibe
CD38 and Plasma Cells in IgAN: Pathogenesis to Therapeutic Target - Heather Reich
Clinical Rationale, Emerging Data, and Clinical Context for CD38-Directed Therapy in the Evolving Landscape of IgAN Therapies - Jürgen Floege

Support is provided by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Meta Tag

Pathway(s) Glomerular Diseases

Pathway(s) Kidney Biology and Physiology

Session Type ES - Educational Symposium

Speaker(s) Shuta Ishibe

Speaker(s) Heather Reich

Speaker(s) Jürgen Floege

Keywords

IgA nephropathy

CD38-targeting therapy

plasmablasts

plasma cells

proteinuria reduction

felzartamab

mezagitamab

complement inhibition

phase 3 trials

IgAN

CD38

pathogenesis

therapeutic target

CD38-directed therapy

emerging data

clinical rationale

Takeda Pharmaceuticals